RALEIGH, N.C., Nov. 24, 2015 /PRNewswire/ -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered in Raleigh, North Carolina, today announced that the company has set a new quarterly earnings record in Q3 of 2015. These earnings represented a 391% quarter on quarter growth posted for Q3 of 2014 to Q3 of 2015.
Clintrax's Q3 earnings reflect the company's rapid growth within the past year. The company has increased its full-time workforce by over 262% since the beginning of 2014. In addition, Clintrax projects 1,801% revenue growth from the 2013 to the 2015 fiscal year. Clintrax has also expanded its global presence this past year by adding offices in the United Kingdom and Mexico, with the establishment of an Asia-Pacific office to take place in December 2015.
"We are thrilled to report another strong quarter. With each consecutive quarter, we're not only meeting but surpassing our internal benchmarks and goals. I believe that our 2016 projections are demonstrative of our continued growth, solidifying Clintrax's place as the global leader in our space," said Brandon Evans, CEO of Clintrax Global.
About Clintrax Global
Clintrax Global, Inc. is a Raleigh-based company specializing in global clinical trial contract negotiation and investigator payments. The company acts as a functional service provider for pharmaceutical/biotechnology companies and CROs during the process of drug development. Clintrax provides these clients with worldwide contract negotiation and payments services to clinical trial sites including small clinics, large hospitals, and multicenter academic institutions in over 60 countries. For more information, please visit clintraxglobal.com.
SOURCE Clintrax Global, Inc.